Abstract: A system and method for determining parameters of stimulation electrical signals for vagus nerve stimulation is discussed. Initial parameters of the signals are selected to provide reliable response to stimulation in physiological measurements of a subject. One or more physiological and neurological indices are determined based on a vagus nerve response model. For a selected vagus nerve activation, the electrical parameters of the signals are varied while monitoring changes in physiological parameters and values of the indices. The electrical parameters are varied until desired response in the physiological measurements and the values of the indices is observed. The electrical parameters are then stored as preferred parameters and can be used to activate the selected vagus nerve of the subject.
Type:
Grant
Filed:
May 20, 2021
Date of Patent:
March 26, 2024
Assignee:
The Feinstein Institutes for Medical Research
Abstract: A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described.
Type:
Grant
Filed:
May 4, 2021
Date of Patent:
February 20, 2024
Assignees:
THE GENERAL HOSPITAL CORPORATION, THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.
Type:
Grant
Filed:
August 30, 2022
Date of Patent:
January 30, 2024
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: A method performed by a first microservice processor includes receiving a first user indication from a first computing device from a plurality of computing devices of a second user that indicates that a first user requested a service of the second user. A first user-specific data container object is generated that includes first user-specific data elements associated with the service provided to the first user. First user-specific service-necessity information data objects are obtained from electronic resources. The first user-specific data elements and the first user-specific service-necessity information data objects are inputted into a machine learning engine to obtain ranked reference-claim data objects. A chosen reference-claim data object from the ranked reference-claim data objects is chosen by the second user to justify providing the service to the first user.
Type:
Grant
Filed:
December 8, 2022
Date of Patent:
January 23, 2024
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, INC.
Inventors:
Howard B. Gold, Konstanine Costalas, John Charles Cheeseborough, Lawrence David Robertson
Abstract: The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.
Type:
Grant
Filed:
April 19, 2018
Date of Patent:
January 16, 2024
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Inventors:
Theodoros Zanos, Todd Levy, Emily Battinelli, Kevin J. Tracey, Chad E. Bouton, Sangeeta Chavan, Harold Silverman
Abstract: Methods and systems are described for detecting the likelihood of patent ductus arteriosus (PDA) in an infant using electrocardiogram and photoplethysmographic pulse signals obtained from the upper body and foot of the infant.
Type:
Grant
Filed:
September 28, 2022
Date of Patent:
January 16, 2024
Assignees:
The Feinstein Institutes for Medical Research, Jerusalem College of Technology
Abstract: Disclosed are apparatuses and methods for reducing or limiting blood loss and reducing bleed time in a subject by combined vagus and trigeminal stimulation. The apparatuses and methods may activate (e.g., electrically) one or more branches of the trigeminal nerve and may concurrently (at overlapping or near-overlapping time) independently activate the vagus nerve. This activation may be invasive or non-invasive.
Type:
Grant
Filed:
January 4, 2023
Date of Patent:
January 2, 2024
Assignee:
The Feinstein Institutes for Medical Research
Abstract: Disclosed are nerve stimulation assemblies adapted to apply stimulation signals to a person's nervous system. The assemblies are adapted to apply such signals to nerves terminating on the outer ear of a person, for example, the auricular branch of the vagus nerve. The assemblies comprise an ear canal extension adapted to fit within an ear canal of the person, a housing connected with the extension, and an electrode arm connected with the housing by a connection member. The connection member is adapted to articulate the electrode arm to position the electrode arm relative to the outer ear. An electrode is connected with a distal end of the arm. When the arm is articulated to a selected orientation and the extension is fitted in the ear canal, the electrode is in electrical contact with a portion of the outer ear innervated by a selected peripheral nerve, such as the vagus nerve.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
October 3, 2023
Assignee:
The Feinstein Institutes for Medical Research
Abstract: Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.
Type:
Application
Filed:
May 30, 2023
Publication date:
September 28, 2023
Applicant:
The Feinstein Institutes for Medical Research
Abstract: Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
July 18, 2023
Assignee:
The Feinstein Institutes for Medical Research
Abstract: The present invention is related to the use of HMGB1 antagonists in the treatment and/or prevention and/or inhibition of acute lung injury in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists, in particular K883, in an effective amount to treat and/or prevent and/or inhibit this condition.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
June 27, 2023
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.
Type:
Grant
Filed:
April 22, 2019
Date of Patent:
May 30, 2023
Assignee:
The Feinstein Institutes for Medical Research
Inventors:
Jared M. Huston, Jason R. Fritz, Seema G. Amin, Christopher J. Czura, Kevin J. Tracey
Abstract: Methods and systems are described for detecting the likelihood of patent ductus arteriosus (PDA) in an infant using electrocardiogram and photoplethysmographic pulse signals obtained from the upper body and foot of the infant.
Type:
Application
Filed:
September 28, 2022
Publication date:
May 25, 2023
Applicants:
The Feinstein Institutes for Medical Research, Jerusalem College of Technology
Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.
Type:
Application
Filed:
August 30, 2022
Publication date:
May 18, 2023
Applicant:
The Feinstein Institutes For Medical Research
Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.
Type:
Application
Filed:
December 19, 2022
Publication date:
April 27, 2023
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
April 25, 2023
Assignee:
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Inventors:
Kevin J. Tracey, Huan Yang, Yousef Al-Abed
Abstract: Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics.
Type:
Application
Filed:
December 2, 2022
Publication date:
April 13, 2023
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Apparatuses and methods for reducing or limiting bleeding in an animal by focused ultrasound (FUS) stimulation of the spleen. The apparatuses and methods may be used treat blood disorders such as hemophilia, or to reduce hemorrhage in surgery or due to traumatic injury. The methods may be non-invasively administered to the patient by transcutaneous application of ultrasound energy.
Type:
Application
Filed:
January 13, 2021
Publication date:
January 19, 2023
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Inventors:
Jared M. HUSTON, Jason R. FRITZ, Catherine W. IMOSSI, Kevin J. TRACEY
Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.
Type:
Grant
Filed:
November 26, 2019
Date of Patent:
January 3, 2023
Assignee:
The Feinstein Institutes for Medical Research